Adverse effects requiring withdrawal/discontinuation of study medication · people with focal or generalized seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time on allocated treatment (retention time) · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Retention [ · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma
Clobazam may leads to higher retention at 6 months (measured by the number of treatment failures… compared with phenytoin (low certainty).
1 finding from 1 review
Improvement of BCVA defined as ≥ 15 ETDRS letters (i.e. 3 ETDRS lines or 0.3 logMAR · people with diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Visual acuity · people with diabetic macular oedema
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Anatomic measures: partial to complete resolution of the macular oedema with stereoscopic fundus photography or biomicroscopy; leakage on fluorescein angiography (IVFA); and, if available, retinal macular thickness with OCT · people with diabetic macular oedema
Subthreshold showed no clear difference in anatomic measures: partial to complete resolution of the macular… compared with standard macular photocoagulation (low certainty).
1 finding from 1 review
RR 0.47 [0.21, 1.03]
Studies not reported
Low
Central retinal thickness at 3 months after surgery; · people with diabetic macular oedema
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Quality of life measures · people with diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Worsening of BCVA defined as ≥ 15 ETDRS letters (i.e. 3 ETDRS lines or 0.3 logMAR · people with diabetic macular oedema
Laser photocoagulation probably leads to lower worsening of BCVA defined as ≥ 15 ETDRS letters (i.e. 3 ETDRS lines… compared with no intervention (moderate certainty).
1 finding from 1 review
RR 0.42 [0.2, 0.9]
Studies not reported
Moderate
Visual acuity · people with diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Anatomic measures: partial to complete resolution of the macular oedema with stereoscopic fundus photography or biomicroscopy; leakage on fluorescein angiography (IVFA); and, if available, retinal macular thickness with OCT · people with diabetic macular oedema
Laser photocoagulation probably leads to higher anatomic measures: partial to complete resolution of the macular… compared with no intervention (moderate certainty).
1 finding from 1 review
RR 1.55 [1.3, 1.86]
Studies not reported
Moderate
Central retinal thickness at 3 months after surgery; · people with diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life measures · people with diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement of BCVA defined as ≥ 15 ETDRS letters (i.e. 3 ETDRS lines or 0.3 logMAR · people with diabetic macular oedema
It is very uncertain whether subthreshold changes improvement of BCVA defined as ≥ 15 ETDRS letters (i.e. 3 ETDRS… compared with standard macular photocoagulation (very low certainty).
1 finding from 1 review
RR 0.31 [0.01, 7.09]
Studies not reported
Very low
Worsening of BCVA defined as ≥ 15 ETDRS letters (i.e. 3 ETDRS lines or 0.3 logMAR · people with diabetic macular oedema
It is very uncertain whether subthreshold changes worsening of BCVA defined as ≥ 15 ETDRS letters (i.e. 3 ETDRS lines… compared with standard macular photocoagulation (very low certainty).
1 finding from 1 review
RR 0.93 [0.15, 5.76]
Studies not reported
Very low
Time to death from any cause (here: overall mortality at 12‐month
Pembrolizumab probably leads to lower time to death from any cause (here: overall mortality at 12‐month compared with chemotherapy (moderate certainty).
1 finding from 1 review
Quality of life (Change from baseline to week 15)
Pembrolizumab may leads to higher quality of life (Change from baseline to week 15) compared with chemotherapy (low certainty).
1 finding from 1 review
Brain tumour response rates: complete response (CR) and partial response (PR) combinedNo. of participants: 847(6 RCTs)
Pembrolizumab probably leads to higher response rate (partial and complete response) compared with chemotherapy (moderate certainty).
1 finding from 1 review